ROIV
Roivant Sciences Ltd. NASDAQ Listed Dec 8, 2020$28.29
Mkt Cap $20.2B
52w Low $10.58
89.6% of range
52w High $30.33
50d MA $28.33
200d MA $20.88
P/E (TTM)
-116.0x
EV/EBITDA
-4.3x
P/B
3.9x
Debt/Equity
0.0x
ROE
-14.2%
P/FCF
-8.7x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$28.33
200d MA
$20.88
Avg Volume
6.0M
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
11-12 St. James's Square · London SW1Y 4LB · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | AMC | -0.30 | -0.24 | +19.9% | 25.82 | +2.1% | +7.2% | -1.2% | -2.0% | -0.2% | -1.1% | — |
| Nov 10, 2025 | AMC | -0.32 | -0.28 | +12.4% | 21.17 | +0.5% | -1.3% | +2.0% | -3.6% | -1.3% | +1.3% | — |
| Aug 11, 2025 | AMC | -0.25 | -0.18 | +27.9% | 11.17 | +1.2% | +3.6% | +3.4% | -1.8% | +0.9% | -0.3% | — |
| May 29, 2025 | AMC | -0.26 | -0.22 | +16.5% | 11.30 | +0.0% | -2.7% | +1.6% | +0.7% | -0.4% | -0.1% | — |
| Feb 10, 2025 | AMC | -0.24 | -0.13 | +45.8% | 10.79 | -0.3% | -2.8% | -0.5% | +0.1% | +1.1% | +1.1% | — |
| Nov 12, 2024 | AMC | -0.25 | -0.29 | -17.4% | 11.64 | +1.6% | +2.7% | -2.6% | -3.8% | -0.4% | +1.3% | — |
| Aug 8, 2024 | AMC | -0.24 | -0.18 | +26.0% | 10.85 | +0.0% | +2.5% | +0.5% | +1.6% | +0.6% | -1.0% | — |
| May 30, 2024 | AMC | -0.26 | -0.23 | +13.0% | 10.39 | +1.1% | -0.3% | +4.8% | -1.2% | +1.4% | -2.4% | — |
| Feb 13, 2024 | AMC | -0.27 | -0.21 | +22.2% | 10.80 | +0.0% | +4.8% | +1.1% | +1.2% | -0.4% | +0.0% | — |
| Nov 13, 2023 | AMC | -0.28 | -0.26 | +7.1% | 9.05 | +3.9% | +2.8% | -2.5% | -0.6% | -0.6% | -1.9% | — |
| Aug 14, 2023 | AMC | -0.26 | -0.38 | -46.2% | 11.71 | +0.1% | -6.3% | -1.5% | -3.1% | +3.8% | +0.8% | — |
| Jun 28, 2023 | AMC | -0.41 | -0.20 | +51.2% | 10.07 | +0.8% | -1.7% | +1.8% | -3.2% | +8.9% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.39 | $29.65 | +0.9% | -0.7% | +2.2% | -2.5% | +0.7% | -0.5% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.85 | $28.44 | +2.1% | +6.0% | +0.7% | -3.2% | +2.6% | +0.6% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.67 | $27.50 | -0.6% | -1.2% | -2.0% | -0.2% | -1.1% | +2.4% |
| Feb 10 | Citigroup | Maintains | Buy → Buy | — | $27.67 | $27.50 | -0.6% | -1.2% | -2.0% | -0.2% | -1.1% | +2.4% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $25.82 | $26.35 | +2.1% | +7.2% | -1.2% | -2.0% | -0.2% | -1.1% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $22.10 | $22.20 | +0.5% | -0.9% | +4.7% | -1.0% | -4.0% | +2.8% |
| Dec 15 | Goldman Sachs | Maintains | Buy → Buy | — | $22.10 | $22.20 | +0.5% | -0.9% | +4.7% | -1.0% | -4.0% | +2.8% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.34 | $21.77 | +2.0% | +3.6% | -0.9% | +4.7% | -1.0% | -4.0% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $21.17 | $21.27 | +0.5% | -1.3% | +2.0% | -3.6% | -1.3% | +1.3% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $18.41 | $18.36 | -0.3% | +1.9% | +4.4% | +2.1% | -2.0% | +1.4% |
| Sep 18 | BofA Securities | Maintains | Neutral → Neutral | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Guggenheim | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | JP Morgan | Maintains | Overweight → Overweight | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Jefferies | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Goldman Sachs | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.11 | $11.15 | +0.4% | +3.0% | +0.1% | +0.4% | +0.3% | -1.2% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.76 | $10.75 | -0.1% | -1.3% | +6.4% | -2.7% | +1.6% | +0.7% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.15 | $10.15 | +0.0% | -1.1% | +3.8% | +3.1% | +2.4% | +0.1% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.79 | $10.76 | -0.3% | -2.8% | -0.5% | +0.1% | +1.1% | +1.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.64 | $11.83 | +1.6% | +2.7% | -2.6% | -3.8% | -0.4% | +1.3% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.00 | $12.03 | +0.2% | -0.7% | +0.4% | -0.6% | -1.8% | +0.7% |
| Sep 11 | BofA Securities | Maintains | Neutral → Neutral | — | $12.19 | $12.27 | +0.7% | +1.6% | -2.1% | -1.5% | +0.8% | +0.1% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.19 | $12.27 | +0.7% | +1.6% | -2.1% | -1.5% | +0.8% | +0.1% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.19 | $11.20 | +0.1% | +2.7% | -0.1% | +2.7% | -0.9% | +1.7% |
| Jul 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.83 | $10.87 | +0.4% | +3.9% | -0.1% | +1.0% | +1.3% | +1.0% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.39 | $10.50 | +1.1% | -0.3% | +4.8% | -1.2% | +1.4% | -2.4% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.46 | $10.52 | +0.6% | +1.3% | +3.2% | -0.4% | -0.2% | +1.4% |
| Apr 3 | Goldman Sachs | Maintains | Buy → Buy | — | $10.92 | $10.92 | +0.0% | +5.4% | +0.0% | +2.0% | -0.9% | -1.9% |
| Apr 3 | Deutsche Bank | Maintains | Buy → Buy | — | $10.92 | $10.92 | +0.0% | +5.4% | +0.0% | +2.0% | -0.9% | -1.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.92 | $10.92 | +0.0% | +5.4% | +0.0% | +2.0% | -0.9% | -1.9% |
| Mar 25 | Truist | Maintains | Buy → Buy | — | $10.15 | $10.16 | +0.1% | -2.0% | +1.3% | +7.5% | -2.8% | -1.0% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.80 | $10.80 | +0.0% | +4.8% | +1.1% | +1.2% | -0.4% | +0.0% |
| Jan 2 | BofA Securities | Maintains | Neutral → Neutral | — | $11.23 | $11.22 | -0.1% | +1.1% | -4.3% | -0.4% | +4.2% | +1.5% |
| Nov 15 | Guggenheim | Maintains | Buy → Buy | — | $9.30 | $9.25 | -0.5% | -2.5% | -0.6% | -0.6% | -1.9% | -1.8% |
| Nov 14 | JP Morgan | Maintains | Overweight → Overweight | — | $9.05 | $9.40 | +3.9% | +2.8% | -2.5% | -0.6% | -0.6% | -1.9% |
| Sep 27 | Goldman Sachs | Maintains | Buy → Buy | — | $12.41 | $12.77 | +2.9% | +6.3% | -4.9% | -6.9% | -10.0% | -0.9% |
| Sep 26 | Truist | Maintains | Buy → Buy | — | $10.21 | $11.80 | +15.6% | +21.5% | +6.3% | -4.9% | -6.9% | -10.0% |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.29 | $11.17 | -1.1% | -1.5% | -2.9% | -4.4% | -1.1% | +1.1% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.68 | $11.63 | -0.4% | +0.6% | +0.3% | -0.8% | +7.7% | -8.7% |
| Aug 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.58 | $11.58 | +0.0% | -0.1% | +1.0% | +0.6% | +0.3% | -0.8% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.96 | $10.99 | +0.3% | +1.7% | +5.0% | -5.1% | +0.3% | +1.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.71 | $11.72 | +0.1% | -6.3% | -1.5% | -3.1% | +3.8% | +0.8% |
| Jul 14 | Truist | Maintains | Buy → Buy | — | $11.60 | $11.99 | +3.4% | +0.6% | +1.1% | +0.1% | -2.3% | -3.6% |
| Jun 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.07 | $10.15 | +0.8% | -1.7% | +1.8% | -3.2% | +8.9% | +0.2% |
| Jun 23 | Truist | Maintains | Buy → Buy | — | $9.97 | $10.00 | +0.3% | -1.7% | -6.3% | -1.4% | +11.3% | -1.7% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.97 | $10.00 | +0.3% | -1.7% | -6.3% | -1.4% | +11.3% | -1.7% |
| Jun 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.65 | $9.52 | -1.3% | +1.5% | -2.7% | +4.6% | -1.7% | -6.3% |
| Jun 9 | JP Morgan | Maintains | Overweight → Overweight | — | $9.58 | $9.63 | +0.5% | +4.7% | -6.1% | +3.8% | -0.7% | +2.2% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Immunovant's batoclimab Phase 3 thyroid eye disease data and brepocitinib advancement could drive near-term clinical catalysts, but investors should await detailed results to assess commercial viability and likelihood of regulatory approval.
Apr 2
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Settlement with Moderna likely ends costly litigation risk for these biotech companies, potentially freeing resources for R&D and improving profit visibility going forward.
Mar 23
8-K · 8.01
!! High
Roivant Sciences Ltd. Common Shares -- 8-K 8.01: Material Event / Announcement
Roivant Sciences doubled its share repurchase authorization to $1 billion, signaling management confidence in the stock's valuation and commitment to returning capital to shareholders.
Mar 3
8-K · 7.01
! Medium
Roivant Sciences Ltd. Common Shares -- 8-K 7.01: Regulation FD Disclosure
Roivant Sciences' FDA acceptance of brepocitinib's NDA with Priority Review for dermatomyositis treatment accelerates the potential approval timeline for this subsidiary asset.
Mar 3
8-K
Roivant Sciences Ltd. Common Shares -- 8-K Filing
Roivant Sciences' brepocitinib showed positive Phase 2 results for cutaneous sarcoidosis, significantly outperforming placebo with a 21.6-point efficacy advantage, supporting potential regulatory approval and commercial viability.
Feb 6
Data updated apr 26, 2026 11:20pm
· Source: massive.com